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The inherited thrombocytopenias are a heterogeneous group of increasingly 
recognised disorders, which can be associated with bleeding of variable severity. 
Their prevalence has been estimated to be around three per 100,000 of the 
population [1] but it is likely that this is an underestimate due to many 
individuals being undiagnosed, wrongly diagnosed or not recorded on registries 
after a correct diagnosis. More recently it has been reported that the prevalence 
of MYH9-related disorders can be as frequent as 1 in 20,000 of the population 
(2). 
 
The inherited nature of the thrombocytopenia has been recognised for decades 
with the main disorders being the May-Hegglin anomaly, Sebastien, Fechtner and 
Epstein syndromes. These disorders were associated with a variable degree of 
renal impairment, deafness and cataracts. Although initially believed to be 
different disorders, when the genes responsible were identified, it became clear 
that all of these syndromes were variants of defects in the same MYH9 gene 
encoding for non-muscle myosin heavy chain A [3].  The nomenclature was 
subsequently changed to reflect this, and they are now known as the MYH9 
related disorders (MYH9-RD). 
 
The recent introduction of high throughput sequencing (HTS), together with the 
formation of consortia with large numbers of clinicians caring for inherited 
thrombocytopenia patients, led to a dramatic increase in the number of genes 
responsible for the disorder. Inherited thrombocytopenias can be syndromic 
predisposing to renal failure, hearing loss and cataracts such are as the MYH9-
RD whilst others such as the RUNX1, ANKRD26 and ETV6 can be associated with 
predisposition to haematological malignancy (4,5).  
 
In contrast to the major advances in the genetic basis of inherited 
thrombocytopenia the management of these disorders has hardly changed, with 
the main therapeutic decision being whether to transfuse platelets or not. Part of 
the difficulty is the variability in the number of platelets, as well as the bleeding 
tendency which is often not directly proportional to the platelet count. A possible 
explanation for this is the variable and often large size of the platelets in some of 
these disorders; since haemostatic reactions take place on the cell surface, 
disorders associated with larger platelets would be expected to be associated 
with less bleeding. Treatment is usually required when patients are actively 
bleeding or to prevent bleeding prior to surgery or invasive procedures. 
 
Platelet transfusions, however, can be problematic because of the potential for 
adverse events. They carry the risk of transfusion transmitted infection, 
alloimmunization with production of platelet specific or HLA antibodies, allergic 
reactions and transfusion related acute lung injury (TRALI). As a result, the use 
of platelet transfusions tends to be avoided if possible and clinicians use 
tranexamic acid sometimes with desmopressin as non-specific haemostatic 
agents to treat these patients. 
 
Thrombopoietin receptor agonists have been available for the treatment of 
immune thrombocytopenia in adults and children for some time. The two 
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products with the longest availability are eltrombopag which is given orally, and 
romiplostim which is administered subcutaneously. In the UK eltrombopag is 
available for use in patients with thrombocytopenia of at least 6 months duration 
whilst romiplostim is approved for ITP of 12 months duration or more. 
 
In an important initial publication from 2010, Pecci and colleagues showed that 
eltrombopag could increase the platelet count of patients with MYH9 related 
thrombocytopenia (6). Twelve patients with a platelet count of <50x109/l were 
treated with 50mg eltrombopag for 3 weeks and those who did not achieve a 
platelet count of >100x109/l received an additional 3 weeks of treatment at 
75mg once daily. Five patients achieved a count of >100x109/l with the 50mg 
dose and an additional 3 achieved this with the 75mg dose. Overall 67% 
achieved a count of >100x109/l, 25% achieved a minor response and a single 
patient did not respond. The treatment was well tolerated, and the bleeding 
symptoms resolved in 8 of 10 patients who had them at study entry (6). 
 
Since it is known that in most forms of inherited thrombocytopenia the 
megakaryocytes respond to TPO receptor agonists (7), the next logical step was 
to investigate these agents for the treatment of other forms of inherited 
thrombocytopenia and this is what Zaninetti and colleagues have done (8). In a 
manuscript published in this issue of Haematologica they report on their 
multicenter prospective investigation of eltrombopag in patients with five 
different types of inherited thrombocytopenia. A total of 24 patients with MYH9-
related disease, ANKRD26-related thrombocytopenia, X-linked/Wiskott-Aldrich 
syndrome, monoallelic Bernard-Soullier syndrome and ITGB3-related 
thrombocytopenia were included. Patients awaiting procedures received an 
escalating dose of 50-75mg eltrombopag for 3-6 weeks, whilst individuals with 
active bleeding received an escalating dose of 25-75mg for up to 16 weeks 
(Figure 1). The responses varied between the different defects but overall 48% 
of the patients responded achieving a platelet count of over 100x109/. All 4 
patients who were having mucosal bleeding on entry, stopped bleeding following 
the eltrombopag treatment. The treatment with eltrombopag was well tolerated 
but one patient with Wiskott Aldrich syndrome discontinued the treatment due 
to deterioration of his eczema (8). 
 
The trial by Zanetti excluded some patients with inherited thrombocytopenia 
and predisposition to haematological malignancy such as those with mutations 
in the RUNX1 (previously known as AML1) and ETV6 genes; ANKRD26 patients 
were, however, included. The evidence that TPO receptor agonists accelerate 
disease progression is controversial. A study of the use of the TPO receptor 
agonist romiplostim in patients with myelodysplasia and thrombocytopenia was 
halted early despite leading to an increase in the platelet count and improvement 
in bleeding symptoms because of concern regarding progression to acute 
myeloid leukemia (AML). In the final analysis, however, the AML progression 
risk was not significant with the hazard ratio being 1.20 and a 95% confidence 
interval of 0.38-3.84 (9). No such concern was observed in a subsequent trial of 
eltrombopag monotherapy in similar settings (10). 
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As it was alluded earlier there are at least 40 different genes associated with 
inherited thrombocytopenia (11). At this stage, it is not known whether patients 
with other gene mutations will respond to eltrombopag in the same way, or 
whether any of these disorders will respond to the other TPO receptor agonists 
such as romiplostim; whilst the answer to both of these questions is likely to be 
yes, currently this is speculation and it needs to be confirmed in clinical trials or 
case series.   
 
Considering the rarity and variety of the inherited thrombocytopenias as well as 
the brief period that most of these individuals require treatment to improve 
their platelet count for, it is unlikely that a pharmaceutical manufacturer will 
perform the required trials to get approval of their drug for this indication. 
 
The study by Zaninetti is important because it establishes eltrombopag as a 
therapeutic entity in the treatment of inherited thrombocytopenia. At this stage 
we do not know if patients with mutations in other genes or even different 
mutations in the same gene will respond the same way, if at all. In view of this, it 
would be sensible to offer patients soon after diagnosis a 3-week therapeutic 
trial of 50mg of eltrombopag daily with the option of another 3 weeks at 75mg 
daily in the non- or poor-responders. In this way it will be known if at periods of 
future need, they are eltrombopag responders or not, in which case they are 
likely to require platelet transfusions. I believe for elective procedures the use of 
eltrombopag as a first line agent is a very reasonable proposition, even when the 
drug is not licensed for this indication.  
 
Although in many countries national registries exist for patients with inherited 
bleeding disorders, these tend to be for individuals with clotting factor 
deficiencies and do not include persons with inherited thrombocytopenia. I 
believe that all patients with inherited thrombocytopenia should be entered in 
registries so that the natural history as well as the response to TPO receptor 
agonist treatment for all the different genetic defects can be established. It is 
unlikely that this will be achieved for most of the disorders without international 
collaboration.  
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Figure Legend 
 
Figure 1. Outline of the phase 2 clinical trial using eltrombopag in patients with 
inherited thrombocytopenia. 
 
 
 
